Nephrocare Health Services Share Price
700.40-6.35 (-0.90%)
+48.63% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | 32% | 32% |
| - | - | - | 15% |
| - | - | - | - |
| 7% | 7% | 11% | 9% |
Peer Comparison
Symbol
APOLLOHOSP
MAXHEALTH
MANIPALHOS
FORTIS
ASTERDM
NH
MEDANTA
LALPATHLAB
KIMS
AGARWALEYE
NEPHROPLUS
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 8,672 | ₹126300 Cr | 60.45 | 40.39 | 207.67 | ₹1942 Cr |
| 993.8 | ₹96763 Cr | 66.42 | 3.31 | 19.84 | ₹1442 Cr |
| 725.9 | ₹95496 Cr | 107.02 | 1.96 | 11.95 | ₹892 Cr |
| 912.15 | ₹68901 Cr | 65.75 | 3.53 | 20.1 | ₹1042 Cr |
| 790 | ₹68592 Cr | 215.24 | 0.31 | 6.76 | ₹464 Cr |
| 1,868.3 | ₹38439 Cr | 47.1 | 10.14 | 65.36 | ₹806 Cr |
| 1,481.6 | ₹38149 Cr | 68.59 | 5.91 | 29.85 | ₹556 Cr |
| 1,877.1 | ₹32259 Cr | 59.53 | 10.11 | 42.51 | ₹505 Cr |
| 765.3 | ₹32231 Cr | 157.77 | 1.04 | 12.74 | ₹241 Cr |
| 509.25 | ₹16249 Cr | 109.52 | 1.43 | 13.88 | ₹133 Cr |
| 700.4 | ₹7108 Cr | 92.5 | 3.19 | 16.66 | ₹77 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|
| ₹282 Cr | ₹266 Cr | ₹260 Cr | ₹228 Cr | ₹219 Cr | ₹197 Cr |
| ₹7 Cr | ₹12 Cr | ₹3 Cr | ₹7 Cr | ₹4 Cr | ₹5 Cr |
| ₹289 Cr | ₹277 Cr | ₹263 Cr | ₹234 Cr | ₹223 Cr | ₹203 Cr |
| ₹242 Cr | ₹238 Cr | ₹221 Cr | ₹200 Cr | ₹187 Cr | ₹171 Cr |
| ₹71 Cr | ₹65 Cr | ₹64 Cr | ₹54 Cr | ₹55 Cr | ₹49 Cr |
| ₹2 Cr | ₹3 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹5 Cr |
| ₹45 Cr | ₹36 Cr | ₹36 Cr | ₹29 Cr | ₹30 Cr | ₹26 Cr |
| ₹36 Cr | ₹33 Cr | ₹32 Cr | ₹24 Cr | ₹25 Cr | ₹20 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Less Impairment of Assets
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| — | — | — | — |
| ₹20 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr |
| ₹18 Cr | ₹13 Cr | ₹6 Cr | ₹8 Cr |
| ₹1078 Cr | ₹566 Cr | ₹402 Cr | ₹375 Cr |
| ₹1078 Cr | ₹566 Cr | ₹402 Cr | ₹375 Cr |
| ₹1116 Cr | ₹584 Cr | ₹414 Cr | ₹389 Cr |
| ₹5 L | ₹96 Cr | ₹123 Cr | ₹81 Cr |
| -₹30 Cr | -₹19 Cr | -₹23 Cr | -₹17 Cr |
| ₹46 Cr | ₹26 Cr | ₹23 Cr | ₹17 Cr |
| ₹6 Cr | ₹5 Cr | ₹3 Cr | ₹4 Cr |
| ₹21 Cr | ₹108 Cr | ₹126 Cr | ₹86 Cr |
| — | — | — | — |
| ₹143 Cr | ₹113 Cr | ₹71 Cr | ₹43 Cr |
| ₹124 Cr | ₹63 Cr | ₹78 Cr | ₹38 Cr |
| ₹13 Cr | ₹101 Cr | ₹93 Cr | ₹92 Cr |
| ₹19 Cr | ₹7 Cr | ₹1 Cr | ₹1 Cr |
| ₹299 Cr | ₹284 Cr | ₹243 Cr | ₹175 Cr |
| ₹1437 Cr | ₹976 Cr | ₹782 Cr | ₹650 Cr |
| ₹23 Cr | ₹226 Cr | ₹243 Cr | ₹196 Cr |
| — | — | — | — |
| ₹841 Cr | ₹679 Cr | ₹564 Cr | ₹386 Cr |
| ₹323 Cr | ₹282 Cr | ₹208 Cr | ₹146 Cr |
| ₹1 Cr | ₹0 | ₹0 | ₹0 |
| ₹517 Cr | ₹396 Cr | ₹356 Cr | ₹239 Cr |
| ₹6 Cr | ₹6 Cr | ₹69 L | ₹32 Cr |
| ₹7 Cr | ₹0 | ₹0 | ₹0 |
| ₹7 Cr | ₹0 | ₹0 | ₹0 |
| ₹23 Cr | ₹10 Cr | ₹16 Cr | ₹10 Cr |
| ₹46 Cr | ₹18 Cr | ₹20 Cr | ₹42 Cr |
| ₹598 Cr | ₹431 Cr | ₹392 Cr | ₹325 Cr |
| — | — | — | — |
| ₹171 Cr | ₹51 Cr | ₹0 | ₹0 |
| ₹33 Cr | ₹27 Cr | ₹26 Cr | ₹26 Cr |
| ₹317 Cr | ₹266 Cr | ₹203 Cr | ₹159 Cr |
| ₹255 Cr | ₹155 Cr | ₹61 Cr | ₹14 Cr |
| ₹8 Cr | ₹6 Cr | ₹7 Cr | ₹4 Cr |
| ₹56 Cr | ₹40 Cr | ₹94 Cr | ₹121 Cr |
| ₹839 Cr | ₹545 Cr | ₹390 Cr | ₹324 Cr |
| ₹540 Cr | ₹261 Cr | ₹147 Cr | ₹150 Cr |
| ₹1437 Cr | ₹976 Cr | ₹782 Cr | ₹650 Cr |
| ₹109 | ₹3,217 | ₹2,310 | ₹2,167 |
| ₹109 | ₹643 | ₹462 | ₹433 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| ₹97 Cr | ₹87 Cr | ₹33 Cr | -₹9 Cr |
| ₹168 Cr | ₹93 Cr | ₹80 Cr | ₹69 Cr |
| -₹6 Cr | -₹44 Cr | -₹33 Cr | -₹53 Cr |
| ₹260 Cr | ₹136 Cr | ₹80 Cr | ₹7 Cr |
| ₹233 Cr | ₹135 Cr | ₹72 Cr | ₹11 Cr |
| -₹410 Cr | -₹125 Cr | -₹51 Cr | -₹78 Cr |
| ₹157 Cr | ₹54 Cr | ₹27 Cr | ₹60 Cr |
| -₹21 Cr | ₹65 Cr | ₹48 Cr | -₹7 Cr |
| ₹126 Cr | ₹61 Cr | ₹14 Cr | ₹19 Cr |
| ₹19 Cr | ₹2 L | -₹1 Cr | ₹2 Cr |
| ₹124 Cr | ₹126 Cr | ₹61 Cr | ₹14 Cr |
Fundamental Ratios
Consolidated
Standalone
No results found